Results 191 to 200 of about 4,101 (234)

Fitness beyond age: Multidisciplinary expert opinion on redefining fitness for targeted therapies in chronic lymphocytic leukemia. [PDF]

Hemasphere
Córdoba R, Stilgenbauer S, Ghia P, Tedeschi A, Roeker L, Rodriguez-Couso M, Mulligan SP, Nabhan SK, Rynne J, López-Fernández T.   +9 more
europepmc   +1 more source

A decade of ibrutinib for CLL with and without TP53 aberration: final report on an investigator-sponsored phase 2 study.

Blood
Itsara A, Rogness VM, Samples L, Yuan CM, Wang HW, Ahn IE, Farooqui MZH, Tian X, Sun C, Tomasulo E, Soto S, Superata J, Bezkorovaynaya L, Hughes TE, Nierman P, Wiestner A.   +15 more
europepmc   +1 more source

Have Fixed-Duration (FD) Regimens Delivered on Their Promise in Chronic Lymphocytic Leukemia and What Is the Future of FD Regimens? A Narrative Review. [PDF]

Adv Ther
Allan JN.
europepmc   +1 more source

Case Report: renal allograft infiltration by chronic lymphocytic leukemia successfully treated with zanubrutinib. [PDF]

Front Oncol
Abboud B, Rodriguez NG, Babar A, Coreas N, Robbins K, Kunwor R.   +5 more
europepmc   +1 more source

Cardiovascular Challenges in Chronic Lymphocytic Leukemia (CLL) Patients Undergoing Bruton Tyrosine Kinase (BTK) Inhibitor Therapy. [PDF]

Eur J Haematol
Oliva S, Molica S.
europepmc   +1 more source

BRUIN 313 and 314 Trials Open the Door for Noncovalent Bruton Tyrosine Kinase Inhibition as Initial Therapy for Chronic Lymphocytic Leukemia. [PDF]

J Clin Oncol
Davids MS.
europepmc   +1 more source

Multiple skin tumors in a patient treated with orelabrutinib for mantle-cell lymphoma: Case report. [PDF]

Medicine (Baltimore)
Fu X, Zhang Y, Zeng L, Zhang Q, Fu X.
europepmc   +1 more source

Practical Management of Cardiovascular Adverse Events with BTKi Treatment in Patients with Chronic Lymphocytic Leukemia: A Consensus Report by Hematologists and Cardiologists

Talha Munir, Eglė Čiburienė, Vasko Graklanov, Мариана Господинова, Ozren Jakšić, Luka Lipar, Imelda Marton, Anna Panovská, Lucia Petríková, Regina Pileckytė, Zoltán Pozsonyi, Miroslav Slanina, Matevž Škerget, Nikola Bulj   +13 more
openalex   +1 more source

UVI5008: the first reversible, non-covalent Bruton's tyrosine kinase epi-inhibitor for B-cell malignancies. [PDF]

J Hematol Oncol
Dell'Aversana C, Sgueglia G, Massaro C, Perricone U, Sarno F, Megchelenbrink WL, Conte M, Carafa V, Campanella A, Frenquelli M, Bordini J, Ghia P, Petrizzi VB, Alvarez R, Nappi D, Chiurazzi F, Tambaro FP, Wierda WG, de Lera AR, Altucci L.   +19 more
europepmc   +1 more source